Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00039182
Other study ID # NCI-2012-02466
Secondary ID SWOG-S0218U10CA0
Status Completed
Phase Phase 2
First received June 6, 2002
Last updated January 23, 2013
Start date May 2002

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. This phase II trial is studying how well erlotinib works in treating patients with malignant mesothelioma of the lung


Description:

PRIMARY OBJECTIVES:

I. Determine the 1-year survival rate in patients with unresectable malignant pleural mesothelioma treated with erlotinib.

II. Determine the response rate in patients with measurable disease treated with this drug.

III. Determine the frequency and severity of toxic effects of this drug in these patients.

IV. Measure epidermal growth factor receptor (EGFR) expression, EGFR gene amplification, and other activation products in the EGFR signaling pathway in tumor samples and correlate with clinical outcomes in patients treated with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months for 2 years and then annually for 1 year.

PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study within 14-18 months.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date
Est. primary completion date June 2007
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Histologically confirmed malignant pleural mesothelioma

- Epithelial

- Sarcomatous

- Biphasic

- Measurable or nonmeasurable disease

- Not amenable to extrapleural pneumonectomy

- No known CNS metastases

- Performance status - Zubrod 0-1

- WBC at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT or SGPT no greater than 1.5 times ULN (5 times ULN if liver involvement of tumor)

- Creatinine no greater than 2 times ULN

- No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation

- No active peptic ulcer disease

- No intractable nausea or vomiting

- Must be able to swallow and/or receive enteral medications via gastrostomy feeding tube

- No known history of the following:

- Dry eye syndrome

- Sjogren's syndrome

- Keratoconjunctivitis sicca

- Exposure keratopathy

- Fuch's dystrophy

- Other active disorders of the cornea

- Not pregnant or nursing

- Fertile patients must use effective contraception

- No HIV-positive patients receiving combination antiretroviral therapy

- No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or stage I or II cancer that is in complete remission

- No prior biologic therapy for this tumor

- No prior chemotherapy for this tumor

- See Disease Characteristics

- At least 3 weeks since prior radiotherapy and recovered

- See Disease Characteristics

- At least 4 weeks since prior major surgery (e.g., thoracotomy or laparotomy), excluding minor surgeries (e.g., mediastinoscopy, thoracoscopy, or minor biopsies)

- Recovered from prior surgery

- No prior surgical procedures affecting absorption

- No prior investigational anticancer agents for this tumor

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
erlotinib hydrochloride
Given orally
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Southwest Oncology Group San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall survival rate Erlotinib hydrochloride will not be of further interest if the true one-year survival rate is 35% or less, but of considerable interest if 55% or more. 1 year No
Primary RECIST response rate Up to 3 years No
Primary Association between EGFR expression with survival and response Up to 3 years No
See also
  Status Clinical Trial Phase
Completed NCT00025207 - Gefitinib in Treating Patients With Malignant Mesothelioma Phase 2
Completed NCT00107432 - Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma. Phase 2
Completed NCT00027703 - Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma Phase 2
Terminated NCT00028782 - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer N/A
Recruiting NCT04213794 - Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients Early Phase 1
Completed NCT01503177 - Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma Phase 1
Completed NCT00243074 - S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery Phase 2
Completed NCT01126346 - Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) N/A
Withdrawn NCT01325753 - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body N/A
Completed NCT00459862 - Pazopanib in Treating Patients With Malignant Pleural Mesothelioma Phase 2
Active, not recruiting NCT01064648 - Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Phase 1/Phase 2
Completed NCT00365053 - PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery Phase 2
Terminated NCT01861301 - Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma Phase 2
Completed NCT00392444 - Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma Phase 2
Completed NCT00309946 - Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery Phase 2
Completed NCT00030498 - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Phase 1
Recruiting NCT03420963 - Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors Phase 1
Withdrawn NCT01105390 - AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma Phase 2